Modality
Gene Editing
MOA
CD3xCD20
Target
TIGIT
Pathway
mTOR
Heart Failure
Development Pipeline
Preclinical
~May 2011
→ ~Aug 2012
Phase 1
~Nov 2012
→ ~Feb 2014
Phase 2
~May 2014
→ ~Aug 2015
Phase 3
~Nov 2015
→ ~Feb 2017
NDA/BLA
May 2017
→ Aug 2029
NDA/BLACurrent
NCT08113525
2,773 pts·Heart Failure
2017-05→2029-08·Terminated
NCT08209580
211 pts·Heart Failure
2025-11→2026-05·Completed
2,984 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-061mo awayPh3 Readout· Heart Failure
2029-08-023.3y awayPh3 Readout· Heart Failure
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Termina…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-05-06 · 1mo away
Heart Failure
Ph3 Readout
2029-08-02 · 3.3y away
Heart Failure
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08113525 | NDA/BLA | Heart Failure | Terminated | 2773 | NT-proBNP |
| NCT08209580 | NDA/BLA | Heart Failure | Completed | 211 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |